Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Patent
1994-01-04
1999-03-30
Scheiner, Laurie
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
4241881, 4242081, 530300, 530324, 530333, 4351723, C07H 2104, A61K 3921, A61K 3800
Patent
active
058891757
ABSTRACT:
The human immunodeficiency virus type 1 (HIV-1) contains the canonical genes gag, pol, env, tat, rev, vif, vpr, vpu, and nef. The tat gene encodes an early regulatory protein that transactivates viral gene expression through interactions with a trans-activation responsive region (TAR). The instant invention is directed toward nucleic acids encoding site-directed trans-dominant Tat variants with reduced trans-activation capabilities as compared to wild-type. These variants are also capable of inhibiting wild-type Tat activity when present in the appropriate molar concentrations. Tat mutants were constructed by introducing single amino acid substitutions at positions 38, 40, 41, 45, and 47 of the wild-type coding region. A further aspect of the invention is directed toward expression cassettes containing these nucleic acids and methods of producing them. These reagents should prove useful in the identification of anti-viral compounds.
REFERENCES:
Cell, vol. 58, No. 1, Jul. 14, 1989, pp. 215-223, "Mutational analysis of HIV-1 Tat minimal domain peptides: identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression".
Nucleic Acids Research, vol. 17, No. 9, 1989, pp. 3551-3561, "Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis".
Embo Journal, vol 7, No. 10, Oct. 10, 1988, pp. 3143-3147, "Functional domains required for tat-induced transcriptional activation of the HIV-1 long terminal repeat".
Green et al., 1989, "Mutational analysis of HIV-1 Tat minimal domain peptides: identification of trans-dominant mutants that suppress HIV-LTR driven gene expression", Cell 58:215-23.
Bahner et al., 1993, "Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes", J. Virol., 67:3199-3207.
Arya, S., 1993, "Human immunodeficiency virus type 2 (HIV-2) trans-activator (tat): functional domains and the search for trans-dominant negative mutants", AIDS Res. Hum. Retro. 9:839-48.
Pearson et al., 1990, "A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat", Proc. Natl. Acad. Sci. USA 87:5079-83.
Balboni et al., 1993, "Inhibition of human immunodeficiency virus reactivation from latency by a tat transdominant negative mutant", J. Med. Virol. 41:289-95.
Feinberg and Trono, 1992, "Intracellular immunization: trans-dominant mutants of HIV gene products as tools for the study and interruption of viral replication", AIDS Res. Hum. Retro. 8:1013-22.
Tindall and Cooper, 1991, "Primary HIV infection: host responses and intervention strategies", AIDS 5:1-14.
Pantaleo et al., 1993, "The immunopathogenesis of human immunodeficiency virus infection", New Engl. J. Med. 328:327-35.
Sambrook et al., 1989, "Molecular cloning: a laboratory manual", Cold Spring Harbor Laboratory Press, chapters 17 and 18.
Holland et al., 1992, Curr. Topics Microbiol. Immunol. 176:1-20.
Goodenow et al., 1989, J. Acquir. Immune Defic. Syndr. 2:344-352.
Gao et al., 1994, J. Virol. 68:7433-7447.
Mehtali Majid
Sorg Tania
Parkin Jeffrey S.
Scheiner Laurie
Transgene S.A.
LandOfFree
Nucleic acids encoding HIV-1 trans-dominant mutants and their us does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acids encoding HIV-1 trans-dominant mutants and their us, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acids encoding HIV-1 trans-dominant mutants and their us will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1216390